Aurobindo Pharma Sign Agreement with COVAXX to Develop and Commercialize COVID-19 Vaccine UB-612 for India and UNICEF
Shots:
- In the agreement- Aurobindo has obtained the exclusive rights to develop- manufacture & sell COVAXX's UB-612 vaccine in India & UNICEF & also non-exclusive rights in other selected emerging & developing markets
- UB-612 is presently being assessed in P-I will be manufactured by Aurobindo in its Hyderabad facility has a manufacturing capacity of 220M doses with an upcoming capacity of ~480M doses by June 2021
- COVAXX's UB-612 is the first multitope- synthetic peptide-based COVID-19 vaccine candidate in P-I and plans to initiate P-II/II by Q1 2021 in Asia- Latin America- and the USA
Ref: PRNewswire | Image: The Loadstar
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
